The results of clinical trials show that IL-17 antagonists are effective in moderate-to-severe plaque psoriasis (15–17), psoriatic arthritis (PsA) (18, 19) and ankylosing spondylitis (AS) (20–22). Here, IL17A is linked to psoriasis vulgaris.